Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

Meissner, Magdalena, Napolitano, Andrea, Thway, Khin, Huang, Paul and Jones, Robin L 2023. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure? Expert Opinion on Pharmacotherapy 24 (12) , pp. 1395-1401. 10.1080/14656566.2023.2224500

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (794kB) | Preview

Abstract

Introduction: Epithelioid sarcoma (ES) is a rare soft tissue sarcoma subtype, predominantly occurring in children and young adults. Despite optimal management of localized disease, approximately 50% of patients develop advanced disease. The management of advanced ES remains challenging due to limited response to conventional chemotherapy and despite novel oral EZH2 inhibitors that have better tolerability but similar efficacy to chemotherapy. Areas covered: We performed a literature review using the PubMed (MEDLINE) and Web of Science databases. We have focused on the role of chemotherapy, targeted agents such as EZH2 inhibitors, potential new targets and immune checkpoint inhibitors and combinations of therapies currently undergoing clinical investigation. Expert opinion: ES is a soft tissue sarcoma with a heterogeneous pathological, clinical, and molecular presentation. In the current era of precision medicine, more trials with targeted therapies and a combination of chemotherapy or immunotherapy with targeted therapies are required to establish optimal treatment for ES.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Taylor and Francis Group
ISSN:	1465-6566
Date of First Compliant Deposit:	14 August 2023
Date of Acceptance:	8 June 2023
Last Modified:	16 Aug 2023 07:34
URI:	https://orca.cardiff.ac.uk/id/eprint/161709

Actions (repository staff only)

Edit Item